ZTS VS UNH Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

ZTS
100/100

ZTS returned 16.56% in the last 12 months. Based on SPY's performance of -13.45%, its performance is above average giving it a score of 100 of 100.

UNH
10/100

UNH returned 6.83% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

ZTS
75/100

21 analysts offer 12-month price targets for ZTS. Together, they have an average target of 0, the most optimistic target put ZTS at 0 within 12-months and the most pessimistic has ZTS at 0.

UNH
88/100

22 analysts offer 12-month price targets for UNH. Together, they have an average target of 562.97, the most optimistic target put UNH at 650 within 12-months and the most pessimistic has UNH at 442.

Technicals

ZTS
82/100

ZTS receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.

UNH
89/100

UNH receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

ZTS
53/100

ZTS has missed earnings 2 times in the last 20 quarters.

UNH
100/100

UNH has missed earnings 0 times in the last 20 quarters.

Profit

ZTS
78/100

Out of the last 20 quarters, ZTS has had 19 profitable quarters and has increased their profits year over year on 11 of them.

UNH
81/100

Out of the last 20 quarters, UNH has had 20 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

ZTS
50/100

ZTS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

UNH
49/100

UNH has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

Dividend

ZTS
35/100

ZTS's most recent dividend was $0.12 per share, based on a share price of $174.62. It was a payout ratio of 17.39% compared to their total earnings.

UNH
57/100

UNH's most recent dividend was $0.90 per share, based on a share price of $540.46. It was a payout ratio of 28.49% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

ZOETIS INC. Summary

New York Stock Exchange / ZTS
Healthcare
Drug Manufacturers - Specialty & Generic
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

UNITEDHEALTH GROUP INCORPORATED (Delaware) Summary

New York Stock Exchange / UNH
Healthcare
Medical - Healthcare Plans
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.